Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Long-term data on antiviral therapy in Korean patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) are limited. This study evaluated the efficacy and safety of entecavir (ETV) and lamivudine (LAM) over 240 weeks. Methods: Treatment-naive patients with HBeAg-negative CHB were randomized to receive ETV 0.5 mg/day or LAM 100 mg/day during the 96 week double-blind phase, followed by open-label treatment through week 240. The primary endpoint was the proportion of patients with virologic response (VR; hepatitis B virus [HBV] DNA<300 copies/mL) at week 24. Secondary objectives included alanine aminotransferase (ALT) normalization and emergence of ETV resistance (week 96), VR and log reduction in HBV DNA levels (week 240), and safety evaluation. Results: In total, 120 patients (>16 years old) were included (ETV, n=56; LAM, n=64). Baseline characteristics were comparable between the two groups. A significantly higher proportion of ETV-treated patients achieved VR compared to LAM at week 24 (92.9% vs. 67.2%, P=0.0006), week 96 (94.6% vs. 48.4%, P<0.0001), and week 240 (95.0% vs. 47.6%, P<0.0001). At week 96, ALT normalization was observed in 87.5% and 51.6% of ETV and LAM patients, respectively (P<0.0001). Virologic breakthrough occurred in one patient (1.8%) receiving ETV and 26 patients (42.6%) receiving LAM (P<0.0001) up to week 96. Emergence of resistance to ETV was not detected. The incidence of serious adverse events was low and unrelated to the study medications. Conclusions: Long-term ETV treatment was superior to LAM, with a significantly higher proportion of patients achieving VR. Both treatments were well tolerated.
Abstract
Background/Aims: Long-term data on antiviral therapy in Korean patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) are limited. This study evaluated the efficacy and safety of entecavir (ETV) and lamivudine (LAM) over 240 weeks. Methods: Treatment-naive patients with HBeAg-negative CHB were randomized to receive ETV 0.5 mg/day or LAM 100 mg/day during the 96 week double-blind phase, followed by open-label treatment through week 240. The primary endpoint was the proportion of patients with virologic response (VR; hepatitis B virus [HBV] DNA<300 copies/mL) at week 24. Secondary objectives included alanine aminotransferase (ALT) normalization and emergence of ETV resistance (week 96), VR and log reduction in HBV DNA levels (week 240), and safety evaluation. Results: In total, 120 patients (>16 years old) were included (ETV, n=56; LAM, n=64). Baseline characteristics were comparable between the two groups. A significantly higher proportion of ETV-treated patients achieved VR compared to LAM at week 24 (92.9% vs. 67.2%, P=0.0006), week 96 (94.6% vs. 48.4%, P<0.0001), and week 240 (95.0% vs. 47.6%, P<0.0001). At week 96, ALT normalization was observed in 87.5% and 51.6% of ETV and LAM patients, respectively (P<0.0001). Virologic breakthrough occurred in one patient (1.8%) receiving ETV and 26 patients (42.6%) receiving LAM (P<0.0001) up to week 96. Emergence of resistance to ETV was not detected. The incidence of serious adverse events was low and unrelated to the study medications. Conclusions: Long-term ETV treatment was superior to LAM, with a significantly higher proportion of patients achieving VR. Both treatments were well tolerated.
참고문헌 (31)
- 김혁, "Recent trends in hepatitis B virus infection in the general Korean population", The Korean Journal of Internal Medicine, 28(4), pp.413~419 (2013), 대한내과학회[DOI]
- Chae HB, "Current status of liver diseases in Korea: hepatitis B", Korean J Hepatol, 15(suppl 6), pp.S13~S24 (2009)
- Hadziyannis SJ, "Hepatitis B e antigen‐negative chronic hepatitis B", Hepatology, 34, pp.617~624 (2001)
- Viganò M, "Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients?", Liver Int, 35(Suppl 1), pp.107~113 (2015)
- Saikia N, "Management of patients with HBeAg-negative chronic hepatitis B", Postgrad Med J, 83, pp.32~39 (2007)
- Brunetto MR, "Outcome of anti-HBe positive chronic hepatitis B in alphainterferon treated and untreated patients: a long term cohort study", J Hepatol, 36, pp.263~270 (2002)
- Selvaraj V, "Challenges face clinicians treating HbeAg negative chronic hepatitis B in HIV", HIV Clin, 23, pp.1~5 (2011)
- European Association for the Study of the Liver, "EASL clinical practice guidelines: Management of chronic hepatitis B virus infection", J Hepatol, 57, pp.167~185 (2012)
- Sarin SK, "Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update", Hepatol Int, 10, pp.1~98 (2016)
- Kao JH, "Hepatitis B genotypes and the response to interferon therapy", J Hepatol, 33, pp.998~1002 (2000)
- 권정현, "The Efficacy and Safety of Peginterferon-α-2a in Korean Patients with Chronic Hepatitis B: A Multicenter Study Conducted in a Real Clinical Setting", Gut and Liver, 7(2), pp.197~205 (2013), 거트앤리버 발행위원회
- Dienstag JL, "Peginterferon therapy for HBeAg-negative chronic hepatitis B: less than meets the eye", Am J Gastroenterol, 105, pp.1770~1772 (2010)
- Si Hyun Bae, "Hepatitis B Virus Genotype C Prevails Among Chronic Carriers of the Virus in Korea", Journal of Korean Medical Science, 20(5), pp.816~820 (2005), 대한의학회
- Kim H, "Molecular epidemiology of hepatitis B virus (HBV) genotypes and serotypes in patients with chronic HBV infection in Korea", Intervirology, 50, pp.52~57 (2007)
- Papatheodoridis GV, "Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues", Liver Int, 31(Suppl 1), pp.95~103 (2011)
- Terrault NA, "AASLD guidelines for treatment of chronic hepatitis B", Hepatology, 63, pp.261~283 (2016)
- "WHO Model List of Essential Medicines for Children" (2015)[URL]
- Chang TT, "A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B", N Engl J Med, 354, pp.1001~1010 (2006)
- Lai CL, "Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B", N Engl J Med, 354, pp.1011~1020 (2006)
- Lim YS, "Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine", Gastroenterology, 147, pp.152~161 (2014)
- Luo J, "Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naïve chronic hepatitis B patients in real life", Int J Med Sci, 10, pp.427~433 (2013)
- Shouval D, "Three years of entecavir re-treatment of HBeAg (-) entecavir patients who previously discontinued entecavir therapy: results from study ETV-901", Hepatology, 48(Suppl 1), pp.722A~723A (2008)
- 명형준, "만성 B형간염 환자에 대한 초치료제로서 엔테카비어의 항바이러스 효과와 그 예측인자", Clinical and Molecular Hepatology, 16(1), pp.57~65 (2010), 대한간학회
- Huang YH, "Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B patients in Taiwan", J Viral Hepat, 10, pp.277~284 (2003)
- Bang SJ, "Clinical course of patients with insufficient viral suppression during entecavir therapy in genotype C chronic hepatitis B", Dig Liver Dis, 45, pp.600~605 (2013)
- Seto WK, "Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicenter prospective study", Gut, 64, pp.667~672 (2015)
- Shouval D, "Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case of continuous antiviral therapy", J Hepatol, 50, pp.289~295 (2009)
- Tenney DJ, "Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naïve patients", J Hepatol, 50, pp.S10~ (2009)
- Lai CL, "Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B", Clin Infect Dis, 36, pp.687~696 (2003)
- Lok AS, "Long-term safety of lamivudine treatment in patients with chronic hepatitis B", Gastroenterology, 125, pp.1714~1722 (2003)
- Lavanchy D, "Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures", J Viral Hepat, 11, pp.97~107 (2004)